Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of gefurulimab (ALXN1720) in adults with generalized myasthenia gravis
MOH_2023-02-07_012327Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Gefurulimab with Placebo (2 arms). Primary endpoint: Change in MG-ADL total score. Started Jan 2023; status: active, not recruiting.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2023-02-07_012327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-07_012327.